Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

555 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Guidelines for the diagnosis and management of adult myelodysplastic syndromes.
Killick SB, Carter C, Culligan D, Dalley C, Das-Gupta E, Drummond M, Enright H, Jones GL, Kell J, Mills J, Mufti G, Parker J, Raj K, Sternberg A, Vyas P, Bowen D; British Committee for Standards in Haematology. Killick SB, et al. Among authors: vyas p. Br J Haematol. 2014 Feb;164(4):503-25. doi: 10.1111/bjh.12694. Epub 2013 Dec 23. Br J Haematol. 2014. PMID: 24372298 Free article. No abstract available.
Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome.
Sternberg A, Killick S, Littlewood T, Hatton C, Peniket A, Seidl T, Soneji S, Leach J, Bowen D, Chapman C, Standen G, Massey E, Robinson L, Vadher B, Kaczmarski R, Janmohammed R, Clipsham K, Carr A, Vyas P. Sternberg A, et al. Among authors: vyas p. Blood. 2005 Nov 1;106(9):2982-91. doi: 10.1182/blood-2005-04-1543. Epub 2005 Aug 2. Blood. 2005. PMID: 16076868 Free article.
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group. Fenaux P, et al. Lancet Oncol. 2009 Mar;10(3):223-32. doi: 10.1016/S1470-2045(09)70003-8. Epub 2009 Feb 21. Lancet Oncol. 2009. PMID: 19230772 Free PMC article. Clinical Trial.
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.
van de Loosdrecht AA, Alhan C, Béné MC, Della Porta MG, Dräger AM, Feuillard J, Font P, Germing U, Haase D, Homburg CH, Ireland R, Jansen JH, Kern W, Malcovati L, Te Marvelde JG, Mufti GJ, Ogata K, Orfao A, Ossenkoppele GJ, Porwit A, Preijers FW, Richards SJ, Schuurhuis GJ, Subirá D, Valent P, van der Velden VH, Vyas P, Westra AH, de Witte TM, Wells DA, Loken MR, Westers TM. van de Loosdrecht AA, et al. Among authors: vyas p. Haematologica. 2009 Aug;94(8):1124-34. doi: 10.3324/haematol.2009.005801. Epub 2009 Jun 22. Haematologica. 2009. PMID: 19546437 Free PMC article.
Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.
Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, Jädersten M, Killick S, Vyas P, Hellström-Lindberg E, Wainscoat JS, Boultwood J. Pellagatti A, et al. Among authors: vyas p. Br J Haematol. 2011 Oct;155(2):272-4. doi: 10.1111/j.1365-2141.2011.08672.x. Epub 2011 Apr 15. Br J Haematol. 2011. PMID: 21492127 Free article. No abstract available.
Cardiac iron overload in transfusion-dependent patients with myelodysplastic syndromes.
Roy NB, Myerson S, Schuh AH, Bignell P, Patel R, Wainscoat JS, McGowan S, Marchi E, Atoyebi W, Littlewood T, Chacko J, Vyas P, Killick SB. Roy NB, et al. Among authors: vyas p. Br J Haematol. 2011 Aug;154(4):521-4. doi: 10.1111/j.1365-2141.2011.08749.x. Epub 2011 Jun 21. Br J Haematol. 2011. PMID: 21689086 Free article.
Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes.
Frisan E, Vandekerckhove J, de Thonel A, Pierre-Eugène C, Sternberg A, Arlet JB, Floquet C, Gyan E, Kosmider O, Dreyfus F, Gabet AS, Courtois G, Vyas P, Ribeil JA, Zermati Y, Lacombe C, Mayeux P, Solary E, Garrido C, Hermine O, Fontenay M. Frisan E, et al. Among authors: vyas p. Blood. 2012 Feb 9;119(6):1532-42. doi: 10.1182/blood-2011-03-343475. Epub 2011 Dec 12. Blood. 2012. PMID: 22160620 Free article.
Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.
Kuendgen A, Lauseker M, List AF, Fenaux P, Giagounidis AA, Brandenburg NA, Backstrom J, Glasmacher A, Hasford J, Germing U; International Working Group on MDS with del(5q). Kuendgen A, et al. Leukemia. 2013 Apr;27(5):1072-9. doi: 10.1038/leu.2012.369. Epub 2012 Dec 21. Leukemia. 2013. PMID: 23257782 Free PMC article.
555 results